Latest Regulatory News

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Ragnar Metals has identified multiple large conductive anomalies at its Viken Project in Sweden, reinforcing the potential for significant uranium, vanadium, and molybdenum mineralisation. These findings, derived from reprocessed VLF geophysics and historical drilling data, set the stage for targeted exploration.

Cochlear Limited posted a 6% increase in HY25 sales revenue driven by strong implant sales but anticipates FY25 profits at the lower end of guidance due to declining services revenue and rising cloud investments.

Cochlear Limited posted a 5% increase in sales revenue to $1.17 billion for the half year ended December 2024, driven by strong cochlear and acoustic implant growth despite a decline in Services revenue. The company anticipates FY25 underlying net profit at the lower end of guidance amid increased cloud investments and prepares for new product launches.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

Pure Foods Tasmania Limited (ASX: PFT) will recommence trading on the ASX from 14 February 2025 following the lifting of its suspension after submitting reissued financial statements with an unqualified audit opinion.

Pure Foods Tasmania has executed key loan extensions with Commonwealth Bank and outlined a comprehensive turnaround strategy to address its financial challenges, despite ongoing material uncertainty over its going concern status.

Embelton Limited has announced a fully franked ordinary dividend of AUD 0.15 per share for the six months ending December 2024, signaling steady shareholder returns.

Delta Lithium has revealed significant progress in its Western Australian lithium and gold assets, underpinned by robust resource estimates and ongoing exploration. The company’s strategic focus on capital discipline and monetising gold positions it well for future growth.

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.